Galsky Matthew D, Diefenbach Michael, Mohamed Nihal, Baker Charles, Pokhriya Sumit, Rogers Jason, Atreja Ashish, Hu Liangyuan, Tsao Che-Kai, Sfakianos John, Mehrazin Reza, Waingankar Nikhil, Oh William K, Mazumdar Madhu, Ferket Bart S
Matthew D. Galsky, Nihal Mohamed, Charles Baker, Sumit Pokhriya, Jason Rogers, Ashish Atreja, Liangyuan Hu, Che-Kai Tsao, John Sfakianos, Reza Mehrazin, Nikhil Waingankar, William K. Oh, Madhu Mazumdar, and Bart S. Ferket, Icahn School of Medicine at Mount Sinai, New York; and Michael Diefenbach, Northwell Health, Great Neck, NY.
JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00116.
Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) for the treatment of muscle-invasive bladder cancer (MIBC), but observational data demonstrate that this approach is underused. A barrier to shared decision making is difficulty in predicting and communicating survival estimates after cystectomy with or without NAC.
We included patients with MIBC from the National Cancer Database treated with cystectomy. A state-transition model was constructed for calculating 5-year death risk using baseline patient-, tumor-, and facility-level variables. Internal-external cross-validation by geographic region was performed. The effect of NAC was integrated using a literature-derived hazard ratio. Bladder cancer-specific and other-cause mortality was estimated from all-cause mortality rates from US life tables. From the state-transition model, a Web-based tool was developed and pilot usability testing performed.
A total of 9,824 patients with MIBC who underwent cystectomy were eligible for inclusion. Median overall survival was 39.6 months (95% CI, 37.4 to 42.4 months). Increasing age, higher clinical T stage, higher comorbidity index, and black race were associated with shorter survival. Private insurance, higher income, and cystectomy at a high-volume facility were associated with longer survival. The prediction model was well calibrated across geographic regions, with observed-to-predicted 5-year death risks ranging from 0.85 to 1.17. Absolute risk reductions with NAC varied from 8.6% to 10.1%. The Web-based tool allowed input of the predictor variables and a user-defined hazard ratio associated with the effect of NAC to generate individualized survival estimates. The tool demonstrated good usability with clinicians.
A Web-based tool was developed to individualize outcome prediction and communication in patients with MIBC treated with cystectomy with or without NAC to facilitate shared decision making.
一级证据支持新辅助化疗(NAC)用于治疗肌层浸润性膀胱癌(MIBC),但观察数据表明这种方法未得到充分利用。共同决策的一个障碍是难以预测和传达膀胱切除术后(无论是否接受NAC)的生存估计。
我们纳入了国家癌症数据库中接受膀胱切除术治疗的MIBC患者。构建了一个状态转换模型,使用患者基线、肿瘤和机构层面的变量来计算5年死亡风险。按地理区域进行内部-外部交叉验证。使用文献得出的风险比纳入NAC的效果。根据美国生命表中的全因死亡率估计膀胱癌特异性死亡率和其他原因死亡率。基于状态转换模型,开发了一个基于网络的工具并进行了试点可用性测试。
共有9824例接受膀胱切除术的MIBC患者符合纳入标准。中位总生存期为39.6个月(95%CI,37.4至42.4个月)。年龄增加、临床T分期较高、合并症指数较高和黑人种族与生存期较短相关。私人保险、较高收入以及在大容量机构进行膀胱切除术与生存期较长相关。预测模型在各地理区域校准良好,观察到的与预测的5年死亡风险范围为0.85至1.17。NAC的绝对风险降低率在8.6%至10.1%之间。基于网络的工具允许输入预测变量以及与NAC效果相关的用户定义风险比,以生成个性化的生存估计。该工具在临床医生中显示出良好的可用性。
开发了一个基于网络的工具,用于对接受或未接受NAC的膀胱切除术治疗的MIBC患者进行个性化的结局预测和沟通,以促进共同决策。